Choosing how to make a peptide is as consequential as choosing what to make. The two foundational routes — solid-phase peptide synthesis (SPPS) and liquid- or solution-phase peptide synthesis (LPPS) — each shine in different situations, and picking the wrong one can cost you time, yield, and money at exactly the wrong stage. This guide breaks down how they differ and how to choose for your molecule.
What is solid-phase peptide synthesis (SPPS)?
In SPPS, the growing peptide chain is anchored to an insoluble resin while amino acids are added one at a time. After each coupling, excess reagents and by-products are simply washed away — no intermediate isolation required. That makes SPPS fast, highly automatable, and well suited to long or complex sequences. It is the workhorse of research-scale and clinical custom peptide synthesis, and it underpins most modern automated synthesis platforms.
- Strengths: speed, automation, handles long and difficult sequences, excellent for research and clinical material.
- Trade-offs: uses excess reagents and solvent per coupling, which raises cost of goods at very large scale.
What is solution-phase / liquid-phase synthesis (LPPS)?
In LPPS, the peptide is assembled in solution, classically by coupling pre-made fragments rather than single residues. Each intermediate is isolated and purified, which is labor-intensive — but it allows tight control and far lower reagent excess. For shorter, well-defined sequences produced at high volume, that efficiency translates into a meaningfully lower cost per kilogram.
- Strengths: reagent-efficient at scale, strong control over defined sequences, attractive economics for commercial volumes.
- Trade-offs: intermediate isolation is slow and labor-heavy; long or highly modified sequences become impractical.
Head to head: how to weigh the choice
There is no universal winner — the right route is the one that fits your molecule and your stage. Four factors usually decide it:
- Length: longer sequences favor SPPS; shorter ones open the door to LPPS.
- Scale: research and clinical quantities favor SPPS; large commercial volumes favor LPPS or hybrid.
- Complexity: cyclizations, non-natural amino acids and conjugations are generally easier by SPPS.
- Cost of goods: at commercial scale, LPPS’ lower reagent use can decisively reduce cost per kilogram.
Rule of thumb: use SPPS to get to the clinic quickly and to handle hard sequences; evaluate LPPS or a hybrid route when volume and cost of goods dominate at commercial scale.
The hybrid route: best of both
In practice, many of today’s highest-volume therapeutic peptides are made by a hybrid strategy: build fragments by SPPS, then couple those fragments in solution. This captures SPPS’ speed for the hard parts while gaining LPPS’ reagent efficiency for the final assembly. It is a common pattern for commercial-scale programs, where scale-up science and process engineering turn a research route into robust, economical production.
How the choice changes across the lifecycle
The route is rarely a one-time decision. A molecule often starts on SPPS for discovery and early clinical material, then — if volumes justify it — migrates toward LPPS or a hybrid process for commercial supply. Planning that transition early, ideally with a partner who runs both, avoids re-developing the process and re-qualifying a supplier later. This is exactly the bridge from research synthesis to GMP peptide manufacturing and, for active ingredients, peptide API supply.
Making the decision
Start from the molecule (length, modifications), then layer in your scale and cost targets and your timeline. If you need clinical material fast or the sequence is challenging, SPPS is almost always the right first move. If you are planning commercial volumes of a shorter, defined peptide, model the economics of LPPS or a hybrid route before locking the process in. For a fuller picture of the end-to-end process, see our complete guide to peptide manufacturing — or talk to our team about the right route for your program.